Levosimendan Zentiva

Levosimendan, the active ingredient in Levosimendan Zentiva, is a calcium sensitizer / potassium channel opener (inodilator) presented as an injectable solution for intravenous use. It is employed to treat acute decompensated heart failure and cardiogenic shock in hospitalized patients.

GNH USA supplies Levosimendan Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and intensive‑care units worldwide, ensuring quality‑assured product delivery and regulatory compliance across multiple markets. The company maintains robust cold‑chain logistics and provides comprehensive documentation for import and clinical use.

Levosimendan acts as an inodilator, improving cardiac performance in acute heart‑failure syndromes. - Acute decompensated heart failure: increases cardiac output and relieves symptoms of congestion. - Cardiogenic shock: stabilizes blood pressure and supports organ perfusion. - Post‑cardiac surgery low‑output syndrome: enhances myocardial contractility to facilitate weaning from mechanical support.

Levosimendan may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hypotension: reduced blood pressure, especially during initial infusion. - Headache: mild to moderate intensity. - Nausea: occasional feeling of queasiness. - Flushing: transient warmth and reddening of skin. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring intervention. - Ventricular arrhythmias: potentially life‑threatening irregular heart rhythms. - Myocardial ischemia: chest pain due to reduced coronary perfusion. - Anaphylactic reaction: rare allergic response with rash, swelling, and respiratory difficulty.

When using Levosimendan, clinicians should observe several precautionary measures to minimize risk. - Cardiovascular monitoring: continuous blood pressure and ECG monitoring during infusion. - Concomitant vasodilators: avoid or adjust doses of other strong vasodilators to prevent excessive hypotension. - Renal or hepatic impairment: use with caution and consider dose adjustments in patients with severe organ dysfunction. - Electrolyte disturbances: correct hypokalemia or hypomagnesemia before administration. - Pregnancy and lactation: safety not established; use only if potential benefit justifies potential risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Levosimendan can interact with other medicines, affecting its safety or efficacy.

Major Interactions (Avoid): - Nitrates or other potent vasodilators: may cause profound hypotension. - Other calcium sensitizers: additive inotropic effect can increase risk of arrhythmias. - Strong CYP3A4 inhibitors: may raise plasma concentrations of levosimendan.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt desired inotropic response. - ACE inhibitors or ARBs: combined effect on blood pressure requires monitoring. - Diuretics: may exacerbate electrolyte imbalances and hypotension.